Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Intravenous replenishment of fluids and calories in patients who cannot take orally,Maintenance of hydration and electrolyte balance,Treatment of hypovolemia,Prevention of dehydration
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
The terminal half-life of infused dextrose is not applicable as glucose is rapidly metabolized; however, exogenous glucose infusion is cleared with a half-life of approximately 15-30 minutes due to insulin-mediated uptake. Sodium and chloride have no defined elimination half-life as they are homeostatically regulated.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the Krebs cycle in cells; sodium and chloride are excreted renally and via sweat; no significant hepatic metabolism.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dextrose is completely metabolized to carbon dioxide and water, with negligible renal excretion of intact glucose under normal conditions. Sodium and chloride are freely filtered by the glomerulus and undergo variable tubular reabsorption; excess is excreted renally. No biliary or fecal elimination.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: not bound to plasma proteins. Sodium: negligible protein binding. Chloride: not significantly protein bound.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose distributes into total body water, approximately 0.55-0.6 L/kg in adults. Sodium and chloride distribute primarily into extracellular fluid, with volumes of distribution of approximately 0.2 L/kg for sodium and 0.25 L/kg for chloride. These reflect rapid equilibration in respective compartments.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% for dextrose, sodium, and chloride. Not applicable for other routes as this formulation is for IV use only.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR <10 m L/min: Avoid or use with caution due to risk of fluid overload and hypernatremia. GFR 10-50 m L/min: Monitor serum sodium and fluid status; adjust rate as needed. No specific dose reduction, but infusion rate may need to be decreased.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment required for Child-Pugh class A or B. For Child-Pugh class C: Use with caution due to potential fluid retention; monitor serum sodium and adjust rate accordingly.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion; dose based on weight and clinical condition. Typical maintenance: 2-4 m L/kg/hour for children. For neonates, rate may be adjusted to 80-100 m L/kg/day. Do not exceed 25 m L/kg/hour.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients: Start at lower end of dosing range (e.g., 100 m L/hour) and titrate based on fluid status, renal function, and cardiac reserve. Monitor for signs of fluid overload and electrolyte imbalance.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to corn-derived products. Do not administer to patients with anuria. Use with caution in patients with congestive heart failure, renal failure, or hyperglycemia.
None.
Risk of hyperglycemia and hyperosmolarity, especially in diabetic or stressed patients,Monitor serum glucose and electrolytes,Use with caution in renal impairment, heart failure, and increased intracranial pressure,Hypotonic solution; may cause hemolysis if administered rapidly,Do not use if solution is discolored or contains particulates
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to dextrose or corn products,Intracranial or intraspinal hemorrhage,Anuria,Severe hyperglycemia with marked glycosuria,Patients with known allergy to any component
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions. However, patients should avoid excessive salt or sugar intake unless directed by a healthcare provider.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. Hyperglycemia or fluid/electrolyte imbalances may pose fetal risks. No first trimester data suggest direct teratogenicity.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Both dextrose and sodium chloride are normal constituents of breast milk. Maternal administration at isotonic and isosmotic concentrations does not alter milk composition measurably. M/P ratio not applicable as endogenous substances. Generally considered compatible with breastfeeding.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Increased plasma volume (30-50%) and glomerular filtration rate during pregnancy may alter pharmacokinetics; however, dextrose and sodium chloride are endogenous substances regulated by homeostasis. No specific dose adjustment required except to monitor and adjust infusion rate based on maternal glucose, hydration status, and electrolyte levels. Pregnancy may unmask glucose intolerance; titrate dextrose infusion to avoid hyperglycemia.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Dextrose 5% and sodium chloride 0.45% is a hypotonic solution. Use cautiously in patients at risk for increased intracranial pressure (e.g., traumatic brain injury) as rapid administration may cause cerebral edema. Avoid in patients with hyperglycemia, as dextrose can worsen glycemic control. Monitor serum sodium closely in patients with impaired renal function or syndrome of inappropriate antidiuretic hormone (SIADH) to prevent hyponatremia.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Tell your healthcare provider if you have diabetes, heart failure, kidney disease, or are on a low-salt diet.,Report symptoms like headache, nausea, confusion, or swelling during the infusion.,Do not consume additional salt or sugar without medical advice while receiving this solution.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose (glucose) is a monosaccharide that serves as a substrate for cellular metabolism, providing energy and restoring blood glucose levels. Sodium chloride (0.45%) provides electrolytes and helps maintain osmolality; the hypotonic solution replaces fluid and electrolytes.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and electrolyte needs. Typical adult rate: 100-200 m L/hour (2-4 m L/kg/hour) for maintenance. Maximum infusion rate: 25 m L/kg/hour. Not to exceed 50 m L/kg/24 hours.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Deferral: Normal maternal glucose homeostasis is essential for fetal development; administration of 5% dextrose is not expected to increase teratogenic risk when properly monitored. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.